Clinicians choose based on efficacy, tolerability, and access. Ruxolitinib has actual adult data. Ryoncil doesn’t. That’s not bias — that’s reality.
The smug little attempt to shame people for being focused on the share price. Let’s be crystal clear: Mesoblast is a publicly listed company on ASX. People bought shares. They expect performance. That’s not “narrow interest” — that’s the entire basis of capital markets. If you want applause for moral superiority, maybe join an NGO or there are multiple charities to donate. But spare us the “loved ones of every investor”
PS: I have a heart, soul, and a strong sense of humanity — and I put it to use where it matters most. But I hold a listed biotech company accountable where i put my hard earned money to get returns without being lectured through fictional sibling analogies and passive-aggressive moralizing.
MSB Price at posting:
$1.78 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)